Gram-Negative Infections | Access and Reimbursement | EU5 | 2017

The hospital-treated gram-negative infection (GNI) market is dominated by highly effective, generically available antibiotics. However, the rising prevalence of multidrug-resistant (MDR) pathogens makes GNIs increasingly challenging to treat. Agents once considered the most potent antibiotics (e.g., carbapenems) are losing efficacy, thereby driving use of severely toxic last-line agents. Merck’s Zerbaxa (ceftolozane/tazobactam) and Pfizer’s Zavicefta (ceftazidime/avibactam), both of which are active against MDR gram-negative pathogens, are newly approved in Europe. Nonetheless, the opportunity for value-based pricing has rekindled interest from pharmaceutical firms, and the late-stage pipeline for new agents that can address the threat of MDR bacteria has swelled accordingly. As EU5 payers, hospitals, and prescribers balance clinical need with budget constraints, the value proposition for new drugs must be tailored to secure optimal market share in what is fast becoming a crowded segment of the GNI market.

    • What attributes must an emerging GNI therapy offer to secure a favorable HTA at national and regional levels in each EU5 country?
    • What do payers consider the primary drivers and considerations for coverage of key emerging GNI antibiotics?
    • What are the most prescribed and most preferred antibiotics for GNI treatment, including therapies for drug-resistance pathogens? How do payer policies influence physician prescribing practices?
    • What impact will newly approved antibiotics like Zerbaxa and Zavicefta have on the GNI market? How will payers receive value-based pricing of new drugs that address the high unmet need for treatment of MDR infections?
  • PRODUCT DESCRIPTION: Access & Reimbursement: Provides in-depth insight regarding the impact of payer policy on physician prescribing behavior so that you can build your market access strategy and optimize your brand positioning.
Login to access report